NGM — NGM Biopharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $128.53m
- -$15.65m
- $4.42m
Annual cashflow statement for NGM Biopharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -42.8 | -102 | -120 | -163 | -142 |
| Depreciation | |||||
| Non-Cash Items | 12 | 16.1 | 36.8 | 34.9 | 26.3 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | -17.9 | -3.7 | 4.21 | -20.7 | -18.4 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -41.2 | -83.5 | -73.2 | -144 | -132 |
| Capital Expenditures | -3.49 | -1.88 | -1.68 | -1.86 | -1.25 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 52.2 | -49.1 | -70 | 16.2 | 116 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 48.7 | -51 | -71.7 | 14.3 | 114 |
| Financing Cash Flow Items | — | -0.613 | 0 | 0 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 181 | 35.5 | 150 | 54.2 | 1.77 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 188 | -99 | 4.78 | -75.9 | -16.1 |